Cargando…

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials

BACKGROUND: The outcomes of patients diagnosed with head and neck squamous cell carcinoma (HNSCC) who are not candidates for local salvage therapy and of those diagnosed with recurrent or metastatic disease are dismal. A relatively new systemic therapy option that emerged in recent years in the trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poulose, Jissy Vijo, Kainickal, Cessal Thommachan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Systematic Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153072/ https://www.ncbi.nlm.nih.gov/pubmed/35662989 http://dx.doi.org/10.5306/wjco.v13.i5.388

Ejemplares similares

Current Status of Organ Preservation in Carcinoma Larynx
por: Bhattacharyya, Tapesh, et al.
Publicado: (2018)

Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer
por: Bhattacharyya, Tapesh, et al.
Publicado: (2018)

Treatment outcomes of squamous cell carcinoma of the lip: A retrospective study
por: Babu, Geethu, et al.
Publicado: (2022)

Treatment Outcomes of Adenoid Cystic Carcinomas of the Head and Neck Region—A Single-Institution Experience
por: Rafi, Malu, et al.
Publicado: (2022)

Artificial Hydration at the end of Life in an Oncology Ward in Singapore
por: Krishna, Lalit Kumar Radha, et al.
Publicado: (2010)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer
por: Nair, Lekha Madhavan, et al.
Publicado: (2017)

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Park, Jong Chul, et al.
Publicado: (2022)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
por: Veigas, Florencia, et al.
Publicado: (2021)

Outcomes of organ preservation treatment in advanced laryngeal carcinoma: A retrospective analysis from a single institution
por: Fasaludeen, Afsar, et al.
Publicado: (2022)

Treatment outcomes and prognostic factors of esthesioneuroblastoma—a retrospective study from South India
por: Nair, Lekha Madhavan, et al.
Publicado: (2023)

Clinical Profile and Treatment Outcomes in Patients Treated with Intensity-Modulated Radiotherapy (IMRT) for Carcinoma Nasopharynx: A Retrospective Analysis
por: Nazeer, Farida, et al.
Publicado: (2021)

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
por: Mei, Zi, et al.
Publicado: (2020)

Sex Disparity for Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Systematic Review
por: Tan, Brandon, et al.
Publicado: (2022)

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review
por: Schanne, Daniel H., et al.
Publicado: (2022)

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
por: de Kort, W. W. B., et al.
Publicado: (2021)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Zhao, Mei, et al.
Publicado: (2023)

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
por: Dong, Hui, et al.
Publicado: (2023)

Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
por: Wang, Hui-Ching, et al.
Publicado: (2020)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
por: Valero, Cristina, et al.
Publicado: (2023)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
por: Yang, Kaili, et al.
Publicado: (2020)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

The Prognostic Role of miR-31 in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis with Trial Sequential Analysis
por: Dioguardi, Mario, et al.
Publicado: (2022)

Current Applications of Artificial Intelligence to Classify Cervical Lymph Nodes in Patients with Head and Neck Squamous Cell Carcinoma—A Systematic Review
por: Santer, Matthias, et al.
Publicado: (2022)

Toll-like Receptor Agonists Are Unlikely to Provide Benefits in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Maddineni, Sainiteesh, et al.
Publicado: (2023)

The Prediction of Biological Features Using Magnetic Resonance Imaging in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
por: van der Hulst, Hedda J., et al.
Publicado: (2023)

Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Economopoulou, Panagiota, et al.
Publicado: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2021)

Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Sakai, Akihiro, et al.
Publicado: (2023)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
por: Evrard, D., et al.
Publicado: (2020)

Residual Lung Defects Among Survivors of Severe COVID-19 Infection
por: Poulose, Vijo
Publicado: (2022)

Early versus late proning in non-intubated COVID-19 pneumonia
por: Poulose, Vijo
Publicado: (2021)

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
por: Perdyan, Adrian, et al.
Publicado: (2023)

Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
por: Lechner, Axel, et al.
Publicado: (2017)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
por: Lee, Yun-Gyoo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t1hin4i3pugsnitrd5k1lmpm21